Aquestive Therapeutics Reports Topline Data From Temperature / pH Study Of Anaphylm Sublingual Film

• Anaphylm pharmacokinetic results unaffected by oral cavity exposure to liquids of different temperatures and pH
• Remains on track to complete Anaphylm supportive clinical studies and expects to request pre-NDA meeting with FDA in the third quarter 2024
• Continues to anticipate filing a New Drug Application (NDA) shortly after completion of its pediatric study of Anaphylm
  
   

WARREN, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today released positive topline pharmacokinetic (PK) data from the temperature / pH study of its product candidate Anaphylm™ (epinephrine) Sublingual Film.   Anaphylm is the Company's first and only orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis.